A Prospective Study of Lipoprotein(a) and the Risk of Myocardial Infarction

JAMA: The Journal of the American Medical Association

Volumn 270, Issue 18, 1993, Pages 2195-2199

  Ridker, Paul M ^a   Hennekens, Charles H ^a   Stampfer, Meir J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A;

ADULT; AGE; AGED; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; CORONARY RISK; HEART INFARCTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; HUMAN; LIPOPROTEIN(A); MALE; MIDDLE AGE; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027366185     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1993.03510180065035     Document Type: Article

References (37)

1. Scanu AM. Lipoprotein(a): a genetic risk factor for premature coronary heart disease. JAMA. 1992; 267:3326-3329.
2. Loscalzo J. Lipoprotein(a): a unique risk factor for atherothrombotic disease. Arteriosclerosis. 1990; 10:671-679.
3. Scanu AM, Lawn RM, Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med. 1991;115:209-218.
4. Scanu AM, Fless GM. Lp(a): lipoprotein(a) heterogeneity and biological relevance. J Clin Invest. 1992;85:1709-1715.
5. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246:904-910.
6. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60.
7. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256:2540-2544.
8. Berg K, Dahlen G, Frick MH. Lp(a) lipoprotein and pre-beta1-lipoprotein in patients with coronary heart disease. Clin Genet. 1974;6:230-235.
9. Dahlen G, Berg K, Gillnas T, Ericson C. Lp(a) lipoprotein/pre-beta1 lipoprotein in Swedish middle aged males and in patients with coronary heart disease. Clin Genet. 1975;7:334-341.
10. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758-765.
11. Albers JJ, Adolphson JL, Hazzard WR. Radio-immunoassay of human plasma Lp(a) lipoprotein. J Lipid Res. 1977;18:331-338.
12. Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnagar D. Apolipoproteins(a), A1, and B and parental history in men with early onset ischaemic heart disease. Lancet. 1988;1:1070-1073.
13. Seed M, Hoppichler F, Reaveley D, et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990;322:1494-1499.
14. Sandkamp M, Funke H, Schulte H, Kohler E, Assman G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem. 1990;36:20-23.
15. Murai A, Miyahara T, Fujimoto N, Matsuda M Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 1986;59:199-204.
16. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici GB. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981;38:51-61.
17. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 1989;78:145-150.
18. Slunga L, Johnson O, Dahlen GH, Eriksson S. Lipoprotein(a) and acute-phase proteins in acute myocardial infarction. Scand J Clin Lab Invest. 1992;52:95-101.
19. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991;89:59-67.
20. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population of middle aged men. BMJ. 1990; 301:1248-1251.
21. Srinivasan SR, Dahlen GH, Jarpa RA, Webber LS, Berenson GS. Racial (black-white) differences in serum lipoprotein(a) distribution and its relation to parental myocardial infarction in children. Circulation. 1991;84:160-167.
22. Parra HJ, Luyeye I, Bouramoue C, Demarquilly C, Fruchart JC. Black-white differences in serum Lp(a) lipoprotein levels. Clin Chim Acta. 1987;167:27-31.
23. Guyton JR, Dahlen GH, Patsch W, Kautz JA, Gotto AM. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis. 1985;5:265-272.
24. Steering Committee of the Physicians' Health Study Research Group. Final report of the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-135.
25. World Heatlth Organization. Ischemic Heart Disease Registers: Report of the Fifth Working Group, Including a Second Revision of the Operating Protocol. Copenhagen 26-29 April 1971. Copenhagen, Denmark: Regional Office for Europe, World Health Organization, 1971.
26. World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death, Based on the Recommendations of the Ninth Revision Conference, 1975. Geneva, Switzerland: World Health Organization; 1977.
27. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
28. Craig WY, Ledue TB. The effects of long term storage on serum Lp(a) levels. Atherosclerosis. 1992; 93:261.
29. Mensink RP, Zock PL, Katan MB, Hornstra G. Effect of dietary cis and trans fatty acids on serum lipoprotein(a) levels in humans. J Lipid Res. 1992; 33:1493-1501.
30. Jauhiainen M, Metso J, Ehnholm C. A comparison of RIA and ELISA methods for Lp(a) quantitation: control of blood cholesterol. In: Program and abstracts of the 55th annual meeting of the European Atherosclerosis Society (EAS); May 1990: 42; Brugge, Belgium.
31. Kostner GM. Standardization of Lp(a) assays. Clin Chim Acta. 1992;211:191-194.
32. Hearn JA, DeMaio SJ, Roubin GS, Hammarstrom M, Sgoutas D. Predictive value of lipoprotein(a) and other serum lipoproteins in the angiographic diagnosis of coronary artery disease. Am J Cardiol. 1990;66:1176-1180.
33. HoeflerG, Harnoncourt F, Paschke E, Mirtl W, Pfeiffer KH, Kostner GM. Lipoprotein(a): a risk factor for myocardial infarction. Arteriosclerosis. 1988;8:398-401.
34. Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J. 1989;1:77-82.
35. Haffner SM, Moss SE, Klein BE, Klein R. Lack of association between lipoprotein(a) concentrations and coronary heart disease mortality in diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Metabolism. 1992;41:194-197.
36. Pearson T, Davidson L, Jenkins P, Rybicki B, Klag M, Thomas J. Lipoprotein(a) levels in blacks vs whites: marked differences in levels and correlations with other lipids. Circulation. 1990;82:475A.
37. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol. 1992;69:1251-1254.